Press releases
3 known investors
ATAI is developing rapid-acting, durable mental health treatments to address unmet needs in psychiatric conditions affecting over one billion people globally. The company combines drug development, healthcare, and commercialization expertise to create evidence-based therapies for large-scale patient impact.
BiotechHealthtechMental Health